The information provided in this report is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
4D Molecular Therapeutics, Inc(NASDAQ:FDMT)


4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has t...
Founded: 2013
CEO: David Kirn
Sector: Healthcare
Industry: Biotechnology
Share this website to your friends
4D Molecular Therapeutics Days Payable Outstanding ttm (DPO)
4D Molecular Therapeutics Op Cashflow Per Share ttm
4D Molecular Therapeutics Free Cashflow Per Share ttm
4D Molecular Therapeutics Cash Per Share ttm
4D Molecular Therapeutics P/S ratio ttm
4D Molecular Therapeutics (GAAP) P/E ratio ttm
4D Molecular Therapeutics P/B ratio ttm
No extra charts and metrics for this ticker.